Altered Expression and Splicing of Ca(2+) Metabolism Genes in Myotonic Dystrophies DM1 and DM2

Overview

Journal Neuropathol Appl Neurobiol

Specialty Neurology

Date 2012 Jul 5

PMID 22758909

Citations 15

Authors

A Vihola

M Sirito

L L Bachinski

O Raheem

M Screen

T Suominen

R Krahe

B Udd

Affiliations

Soon will be listed here.

Abstract

Aims: Myotonic dystrophy types 1 and 2 (DM1 and DM2) are multisystem disorders caused by similar repeat expansion mutations, with similar yet distinct clinical features. Aberrant splicing of multiple effector genes, as well as dysregulation of transcription and translation, has been suggested to underlie different aspects of the complex phenotypes in DM1 and DM2. Ca(2+) plays a central role in both muscle contraction and control of gene expression, and recent expression profiling studies have indicated major perturbations of the Ca(2+) signalling pathways in DM. Here we have further investigated the expression of genes and proteins involved in Ca(2+) metabolism in DM patients, including Ca(2+) channels and Ca(2+) binding proteins.

Methods: We used patient muscle biopsies to analyse mRNA expression and splicing of genes by microarray expression profiling and RT-PCR. We studied protein expression by immunohistochemistry and immunoblotting.

Results: Most of the genes studied showed mRNA up-regulation in expression profiling. When analysed by immunohistochemistry the Ca(2+) release channel ryanodine receptor was reduced in DM1 and DM2, as was calsequestrin 2, a sarcoplasmic reticulum lumen Ca(2+) storage protein. Abnormal splicing of ATP2A1 was more pronounced in DM2 than DM1.

Conclusions: We observed abnormal mRNA and protein expression in DM affecting several proteins involved in Ca(2+) metabolism, with some differences between DM1 and DM2. Our protein expression studies are suggestive of a post-transcriptional defect(s) in the myotonic dystrophies.

Citing Articles

A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1.

Garcia-Puga M, Gerenu G, Bargiela A, Espinosa-Espinosa J, Mosqueira-Martin L, Sagartzazu-Aizpurua M Cells. 2024; 13(23).

PMID: 39682688 PMC: 11639790. DOI: 10.3390/cells13231939.

Identification of DAPK1 as an autophagy-related biomarker for myotonic dystrophy type 1.

Hu M, Ge M, Li H, Zhang B, Li G Front Genet. 2022; 13:1022640.

PMID: 36338967 PMC: 9634726. DOI: 10.3389/fgene.2022.1022640.

Mice lacking MBNL1 and MBNL2 exhibit sudden cardiac death and molecular signatures recapitulating myotonic dystrophy.

Lee K, Seah C, Li C, Chen Y, Chen C, Wu C Hum Mol Genet. 2022; 31(18):3144-3160.

PMID: 35567413 PMC: 9476621. DOI: 10.1093/hmg/ddac108.

and as Potential Biomarkers of Diabetes-Related Sepsis.

Wang X, Wang L, Yu B Biomed Res Int. 2022; 2022:9463717.

PMID: 35445133 PMC: 9015863. DOI: 10.1155/2022/9463717.

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model.

Overby S, Cerro-Herreros E, Gonzalez-Martinez I, Varela M, Seoane-Miraz D, Jad Y Mol Ther Nucleic Acids. 2022; 27:1146-1155.

PMID: 35282418 PMC: 8888893. DOI: 10.1016/j.omtn.2022.02.003.

References

Savkur R, Philips A, Cooper T, Dalton J, Moseley M, Ranum L . Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet. 2004; 74(6):1309-13. PMC: 1182097. DOI: 10.1086/421528. View

Bachinski L, Udd B, Meola G, Sansone V, Bassez G, Eymard B . Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet. 2003; 73(4):835-48. PMC: 1180606. DOI: 10.1086/378566. View

Mankodi A, Takahashi M, Jiang H, Beck C, Bowers W, Moxley R . Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell. 2002; 10(1):35-44. DOI: 10.1016/s1097-2765(02)00563-4. View

Orengo J, Ward A, Cooper T . Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol. 2011; 69(4):681-90. PMC: 3082633. DOI: 10.1002/ana.22278. View

Kimura T, Pace S, Wei L, Beard N, Dirksen R, Dulhunty A . A variably spliced region in the type 1 ryanodine receptor may participate in an inter-domain interaction. Biochem J. 2006; 401(1):317-24. PMC: 1698670. DOI: 10.1042/BJ20060686. View

Osborne R, Lin X, Welle S, Sobczak K, ORourke J, Swanson M . Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet. 2009; 18(8):1471-81. PMC: 2664149. DOI: 10.1093/hmg/ddp058. View

Brook J, McCurrach M, Harley H, Buckler A, Church D, Aburatani H . Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992; 68(4):799-808. DOI: 10.1016/0092-8674(92)90154-5. View

Petersen O, Michalak M, Verkhratsky A . Calcium signalling: past, present and future. Cell Calcium. 2005; 38(3-4):161-9. DOI: 10.1016/j.ceca.2005.06.023. View

Pelletier R, Hamel F, Beaulieu D, Patry L, Haineault C, Tarnopolsky M . Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neurobiol Dis. 2009; 36(1):181-90. DOI: 10.1016/j.nbd.2009.07.009. View

10.

Lee J, Cooper T . Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans. 2009; 37(Pt 6):1281-6. PMC: 3873089. DOI: 10.1042/BST0371281. View

11.

Udd B, Meola G, Krahe R, Thornton C, Ranum L, Bassez G . 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord. 2006; 16(6):403-13. DOI: 10.1016/j.nmd.2006.03.010. View

12.

Udd B, Krahe R, Wallgren-Pettersson C, Falck B, Kalimo H . Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes?. Neuromuscul Disord. 1997; 7(4):217-28. DOI: 10.1016/s0960-8966(97)00041-2. View

13.

Savkur R, Philips A, Cooper T . Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001; 29(1):40-7. DOI: 10.1038/ng704. View

14.

Garbino A, van Oort R, Dixit S, Landstrom A, Ackerman M, Wehrens X . Molecular evolution of the junctophilin gene family. Physiol Genomics. 2009; 37(3):175-86. PMC: 2685503. DOI: 10.1152/physiolgenomics.00017.2009. View

15.

Udd B, Meola G, Krahe R, Thornton C, Ranum L, Day J . Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. 3rd Workshop, 14-16 February 2003, Naarden, The Netherlands. Neuromuscul Disord. 2003; 13(7-8):589-96. DOI: 10.1016/s0960-8966(03)00092-0. View

16.

Chen W, Wang Y, Abe Y, Cheney L, Udd B, Li Y . Haploinsuffciency for Znf9 in Znf9+/- mice is associated with multiorgan abnormalities resembling myotonic dystrophy. J Mol Biol. 2007; 368(1):8-17. DOI: 10.1016/j.jmb.2007.01.088. View

17.

Sammons M, Antons A, Bendjennat M, Udd B, Krahe R, Link A . ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2. PLoS One. 2010; 5(2):e9301. PMC: 2823779. DOI: 10.1371/journal.pone.0009301. View

18.

Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M . MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 2010; 12(4):341-351. DOI: 10.1016/j.cmet.2010.07.008. View

19.

Buj-Bello A, Furling D, Tronchere H, Laporte J, Lerouge T, Butler-Browne G . Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum Mol Genet. 2002; 11(19):2297-307. DOI: 10.1093/hmg/11.19.2297. View

20.

Kuyumcu-Martinez N, Wang G, Cooper T . Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007; 28(1):68-78. PMC: 2083558. DOI: 10.1016/j.molcel.2007.07.027. View